Literature DB >> 32468256

High resolution melting profiles (HRMPs) obtained by magnetic induction cycler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment.

Giorgia Mazzuccato1, Maria De Bonis1, Vittoria Carboni2, Claudia Marchetti2,3, Andrea Urbani4,5, Giovanni Scambia2,3, Ettore Capoluongo6, Anna Fagotti2,3, Angelo Minucci7.   

Abstract

Resistance can be the result of secondary tissue variants (STVs), which restore the open reading frame of the germline BRCA allele, producing functional BRCA protein in germline BRCA1/2 (BRCA) pathogenic variant (PV) carriers, treated with platinum-based chemotherapy or poly-(ADP-ribose) polymerase inhibitors (PARP-1). We reported recently a BRCA2 mutant high grade serous ovarian cancer (HGSOC) patient with acquired resistance to the PARP-1 olaparib due to a STV detected by next generation tumor sequencing (NGTS). The aim of this study was to evaluate the versatility of the high-resolution melting analysis (HRMA) obtained by magnetic induction cycler (MIC) to monitor the BRCA2 status in formalin-fixed paraffin-embedded (FFPE) tissue samples of this patient and to compare the results obtained by NGTS. HRMA highlighted the BRCA2 STV previously detected in the IIIrd HGSOC recurrence following the tissue BRCA2 tissue status comparing the high resolution melting profiles (HRMPs). HRMPs differentiate not only BRCA2 alleles, but also their different allele abundance. We underline that (1) the MIC uses a latest generation technology guaranteeing temperature uniformity and maintenance in each well allowing high and accurate performance to obtain reported results and (2) the HRMA maintains a high sensitivity and specificity when it is performed on FFPE samples. Finally, this study represents an additional use of the HRMA, confirming its extreme versatility in the diagnostic environment.

Entities:  

Keywords:  BRCA1/2 genes; High grade serous ovarian cancer; High resolution melting analysis; High resolution melting profiles; Next generation tumor sequencing; PARP-1

Mesh:

Substances:

Year:  2020        PMID: 32468256     DOI: 10.1007/s11033-020-05504-5

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  15 in total

1.  High-resolution melting analysis to screen the ST18 gene functional risk variant for pemphigus vulgaris: The occasion to open a debate on its usefulness in clinical setting.

Authors:  Maria De Bonis; Elisa De Paolis; Giovanni Luca Scaglione; Luca Fania; Maria Michela Lavieri; Cinzia Mazzanti; Giovanni Di Zenzo; Angelo Minucci; Ettore Capoluongo
Journal:  Exp Mol Pathol       Date:  2019-03-26       Impact factor: 3.362

2.  Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Authors:  Antonio González-Martín; Bhavana Pothuri; Ignace Vergote; René DePont Christensen; Whitney Graybill; Mansoor R Mirza; Colleen McCormick; Domenica Lorusso; Paul Hoskins; Gilles Freyer; Klaus Baumann; Kris Jardon; Andrés Redondo; Richard G Moore; Christof Vulsteke; Roisin E O'Cearbhaill; Bente Lund; Floor Backes; Pilar Barretina-Ginesta; Ashley F Haggerty; Maria J Rubio-Pérez; Mark S Shahin; Giorgia Mangili; William H Bradley; Ilan Bruchim; Kaiming Sun; Izabela A Malinowska; Yong Li; Divya Gupta; Bradley J Monk
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

3.  Can somatic BRCA2 status solve a case of olaparib monotherapy resistance?

Authors:  Antonella Pietragalla; Angelo Minucci; Claudia Marchetti; Giovanni Scambia; Anna Fagotti
Journal:  Int J Gynecol Cancer       Date:  2019-09-19       Impact factor: 3.437

4.  Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

Authors:  Robert L Coleman; Gini F Fleming; Mark F Brady; Elizabeth M Swisher; Karina D Steffensen; Michael Friedlander; Aikou Okamoto; Kathleen N Moore; Noa Efrat Ben-Baruch; Theresa L Werner; Noelle G Cloven; Ana Oaknin; Paul A DiSilvestro; Mark A Morgan; Joo-Hyun Nam; Charles A Leath; Shibani Nicum; Andrea R Hagemann; Ramey D Littell; David Cella; Sally Baron-Hay; Jesus Garcia-Donas; Mika Mizuno; Katherine Bell-McGuinn; Danielle M Sullivan; Bruce A Bach; Sudipta Bhattacharya; Christine K Ratajczak; Peter J Ansell; Minh H Dinh; Carol Aghajanian; Michael A Bookman
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

5.  Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.

Authors:  Elizabeth M Swisher; Wataru Sakai; Beth Y Karlan; Kaitlyn Wurz; Nicole Urban; Toshiyasu Taniguchi
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

6.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.

Authors:  Wataru Sakai; Elizabeth M Swisher; Beth Y Karlan; Mukesh K Agarwal; Jake Higgins; Cynthia Friedman; Emily Villegas; Céline Jacquemont; Daniel J Farrugia; Fergus J Couch; Nicole Urban; Toshiyasu Taniguchi
Journal:  Nature       Date:  2008-02-10       Impact factor: 49.962

7.  Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.

Authors:  Louise J Barber; Shahneen Sandhu; Lina Chen; James Campbell; Iwanka Kozarewa; Kerry Fenwick; Ioannis Assiotis; Daniel Nava Rodrigues; Jorge S Reis Filho; Victor Moreno; Joaquin Mateo; L Rhoda Molife; Johann De Bono; Stan Kaye; Christopher J Lord; Alan Ashworth
Journal:  J Pathol       Date:  2013-02       Impact factor: 7.996

8.  Diagnostic accuracy of high resolution melting analysis for detection of KRAS mutations: a systematic review and meta-analysis.

Authors:  Yue-Ping Liu; Hai-Yan Wu; Xiang Yang; Han-Qing Xu; Dong Chen; Qing Huang; Wei-Ling Fu
Journal:  Sci Rep       Date:  2014-12-17       Impact factor: 4.379

9.  Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies.

Authors:  Hongdo Do; Alexander Dobrovic
Journal:  Mol Cancer       Date:  2009-10-08       Impact factor: 27.401

10.  Resistance to therapy caused by intragenic deletion in BRCA2.

Authors:  Stacey L Edwards; Rachel Brough; Christopher J Lord; Rachael Natrajan; Radost Vatcheva; Douglas A Levine; Jeff Boyd; Jorge S Reis-Filho; Alan Ashworth
Journal:  Nature       Date:  2008-02-10       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.